KO’s article published on June 27, 2022 highlighted Colorado’s crackdown on most non-compete restrictions. HB 22-1317 has now been codified as CRS 8-2-113 and became effective on August 10, 2022. This new law effectively renders unenforceable most post-employment non-competes and other restrictive covenants, including customer non-solicitation restrictions, for Colorado residents.…

The real business implications of Colorado’s “new” non-compete legislation Recent updates to Colorado’s non-compete statute have created a buzz among business leaders and employment law experts. Through SB 21-271, the Colorado General Assembly, as of March 1, 2022, added a key provision to Colorado’s non-compete statute, C.R.S. § 8-2-113 (the…

Imagine stepping away from your job for two full months, with full pay and benefits, while all your work is covered by your team. That’s sixty days with no Zoom meetings, calls or emails – and it’s something that’s hard to imagine for most people. That’s because most professionals have…

Force majeure, supply chain agreements, commercial contracts and remote customer service — these are just a few of the many areas businesses are rethinking due to the COVID-19 pandemic. For life science companies, these areas take on significant and often urgent meaning as they apply to the pharmaceutical production and…

In a tight labor market, it’s often the benefits and perks that help employers compete for talent. One key benefit an employer must consider is vacation. Should vacation be offered, and if so, how much and how should it be structured? What’s the real value of vacation to employees and…

Most life sciences companies negotiate numerous commercial contracts each year and must rely on big industry players for essential testing, supply and manufacturing partnerships. But these relationships can feel very unbalanced because large vendors seem to have far more negotiating power than any emerging company. Less favorable terms can have…

2019 is off to a fast start in the life science, pharmaceutical and medical device industries with unprecedented market growth. Life sciences, in particular, continue on an upward trend, accounting for nearly 15 percent of venture deal flow in 2018, more than 60 percent of which were deals of $50…